The quarter was broadly in line with expectations, not a clean beat. Reported GAAP EPS was $(1.04), just below the published consensus near $(1.03), while collaboration revenue of $3.8 million was essentially in line with estimates near $3.79 million.
| Metric | Q2 2026 | Q2 2025 | Market read |
|---|---|---|---|
| Collaboration and license revenue | $3.8M | $0.0M | Roughly in line with ~$3.79M consensus (Statements of Operations) |
| R&D expense | $68.3M | $48.0M | Up 42%, reflecting Phase 3 execution (Statements of Operations) |
| Net loss | $(72.9)M | $(54.7)M | Wider loss as development spending rises (Statements of Operations) |
| GAAP EPS | $(1.04) | $(0.98) | Slightly below roughly $(1.03) consensus (Statements of Operations) |
| Cash, equivalents and marketable securities | $430.6M | $514.0M at Dec. 31, 2025 | Cash declined during the first half (Balance Sheet Data) |
The real incremental news is financing flexibility, not the income statement. 4DMT secured a Hercules credit facility of up to $200 million and drew $20 million initially (Corporate Highlights). That adds optional liquidity, but it is debt rather than nondilutive funding; the company still says its current operating plan is funded into the second half of 2028 based on cash and expected Otsuka payments (Cash Position).
Clinical execution remains on schedule, but the decisive evidence is still far away. Enrollment is complete for both wet-AMD Phase 3 studies, with topline data expected in Q2 2027 for 4FRONT-1 and the second half of 2027 for 4FRONT-2 (4D-150 for Wet AMD). The encouraging PRISM two-year data were already presented on July 18, 2026, so that evidence is partly known rather than a fresh surprise (PRISM Phase 1/2 Clinical Trial).
The net read is mixed: steady progress, but no new efficacy inflection. The filing preserves the 4D-150 timeline and strengthens balance-sheet flexibility, while the quarter itself slightly missed on EPS and carries materially higher R&D costs. With the major wet-AMD readouts not due until 2027, the October 21 Investor Day is the next named event likely to add commercial detail (Corporate Highlights).
Read the original 8-K on SEC EDGAR ↗